Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells (Q39611793)

13 September 2017

Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells (English)

1 reference

13 September 2017

1 reference

acute myeloid leukemia

1 reference

Danian Nie

1

1 reference

13 September 2017

Kezhi Huang

2

1 reference

13 September 2017

Songmei Yin

3

1 reference

13 September 2017

Yiqing Li

4

1 reference

13 September 2017

Shuangfeng Xie

5

1 reference

13 September 2017

Liping Ma

6

1 reference

13 September 2017

Xiuju Wang

7

1 reference

13 September 2017

Yudan Wu

8

1 reference

13 September 2017

Jie Xiao

9

1 reference

13 September 2017

language of work or name

1 reference

18 June 2012

1 reference

13 September 2017

1 reference

13 September 2017

53

1 reference

13 September 2017

2487-2495

1 reference

13 September 2017

12

1 reference

Valproic acid exerts differential effects on CXCR4 expression in leukemic cells.

13 September 2017

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Mantle cell lymphoma activation enhances bortezomib sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Phase I study of bortezomib in refractory or relapsed acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Valproic acid for the treatment of myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Over-expression of cyclin D1 induces glioma invasion by increasing matrix metalloproteinase activity and cell motility.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

SKP2 siRNA inhibits the degradation of P27kip1 and down-regulates the expression of MRP in HL-60/A cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Telomerase activity and telomere length in human tumor cells with acquired resistance to anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Inhibition of telomerase activity and human telomerase reverse transcriptase gene expression by histone deacetylase inhibitor in human brain cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

Presentation of telomerase reverse transcriptase, a self-tumor antigen, is down-regulated by histone deacetylase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.698273

10.3109/10428194.2012.698273

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference